505082-91-7

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
6-(2-Fluorophenyl)-nicotinic acid is utilized as a therapeutic agent in pharmaceutical research and drug development due to its potential to treat various conditions. Its anti-inflammatory and analgesic properties make it a promising candidate for the management of pain and inflammation.
Used in Cancer Treatment:
In the field of oncology, 6-(2-Fluorophenyl)-nicotinic acid is employed as a potential anti-cancer agent. It has been studied for its ability to target and inhibit the growth of cancer cells, making it a valuable asset in the development of novel cancer therapies.
Used in Neurological Disorder Treatment:
6-(2-Fluorophenyl)-nicotinic acid is also being investigated for its potential use in treating neurological disorders. Its ability to modulate cellular signaling pathways suggests that it may have neuroprotective effects and could be beneficial in managing conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
Used in Biochemical and Pharmacological Research:
6-(2-Fluorophenyl)-nicotinic acid is used as a research tool in the fields of biochemistry and pharmacology. Its role in modulating cellular signaling pathways provides valuable insights into the underlying mechanisms of various diseases and contributes to the discovery of new therapeutic targets and drug candidates.

Upstream product

• 6311-35-9 6-bromonicotinic acid 
• 1993-03-9 o-fluorophenylboronic acid 
• 1033844-92-6 tert-butyl 6-(2-fluorophenyl)nicotinate 

Downstream Products

• 1033844-11-9 6-(2-fluorophenyl)-N-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]nicotinamide 
• 582324-65-0 C₂₁H₁₄FN₃O 

Relevant academic research and scientific papers

Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models

Activation of prostanoid EP2 receptor exacerbates neuroinflammatory and neurodegenerative pathology in central nervous system diseases such as epilepsy, Alzheimer's disease, and cerebral aneurysms. A selective and brain-permeable EP2 antagonist will be useful to attenuate the inflammatory consequences of EP2 activation and to reduce the severity of these chronic diseases. We recently developed a brain-permeable EP2 antagonist 1 (TG6-10-1), which displayed anti-inflammatory and neuroprotective actions in rodent models of status epilepticus. However, this compound exhibited moderate selectivity to EP2, a short plasma half-life in rodents (1.7 h) and low aqueous solubility (27 μM), limiting its use in animal models of chronic disease. With lead-optimization studies, we have developed several novel EP2 antagonists with improved water solubility, brain penetration, high EP2 potency, and selectivity. These novel inhibitors suppress inflammatory gene expression induced by EP2 receptor activation in a microglial cell line, reinforcing the use of EP2 antagonists as anti-inflammatory agents.

Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1

6-Phenylnicotinamide (2) was previously identified as a potent TRPV1 antagonist with activity in an in vivo model of inflammatory pain. Optimization of this lead through modification of both the biaryl and heteroaryl components has resulted in the discovery of 6-(4-fluorophenyl)-2-methyl-N-(2-methylbenzothiazol-5-yl)nicotinamide (32; SB-782443) which possesses an excellent overall profile and has been progressed into pre-clinical development.

Nicotinamide Derivatives

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment o